日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

接受美洛氟芬和地塞米松治疗的复发/难治性多发性骨髓瘤患者的健康相关生活质量:来自 III 期 OCEAN 研究的分析

Schjesvold, Fredrik H; Ludwig, Heinz; Delimpasi, Sossana; Robak, Pawel; Coriu, Daniel; Tomczak, Waldemar; Pour, Ludek; Spicka, Ivan; Dimopoulos, Meletios-Athanasios; Masszi, Tamas; Chernova, Natalia G; Sandberg, Anna; Thuresson, Marcus; Norin, Stefan; Bakker, Nicolaas A; Mateos, Maria-Victoria; Richardson, Paul G; Sonneveld, Pieter

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Belantamab mafodotin:三线抗化疗暴露后复发和/或难治性多发性骨髓瘤脆弱患者的重要治疗选择

Mateos, Maria Victoria; Weisel, Katja; Terpos, Evangelos; Delimpasi, Sossana; Kastritis, Efstathios; Zamagni, Elena; Delforge, Michel; Ocio, Enrique; Katodritou, Eirini; Gay, Francesca; Larocca, Alessandra; Leleu, Xavier; Otero, Paula Rodriguez; Schjesvold, Fredik; Cavo, Michele; Dimopoulos, Meletios A

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

来那度胺末次给药剂量、疗程和免疫调节剂(IMiD)停药间隔对接受泊马度胺/地塞米松治疗的多发性骨髓瘤患者的影响

Kastritis, Efstathios; Roussou, Maria; Gavriatopoulou, Maria; Kanellias, Nikolaos; Migkou, Magdalini; Eleutherakis-Papaiakovou, Evangelos; Ziogas, Dimitrios C; Fotiou, Despina; Ntanasis-Stathopoulos, Ioannis; Dialoupi, Ioanna; Giannouli, Stavroula; Tsirigotis, Panagiotis; Delimpasi, Sossana; Mparmparousi, Despina; Spyropoulou-Vlachou, Mairylin; Xirokosta, Aikaterini; Terpos, Evangelos; Dimopoulos, Meletios A

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group

希腊骨髓瘤研究组开展的一项多中心全国性研究:新型药物时代原发性浆细胞白血病预后和结局的真实世界数据

Katodritou, Eirini; Terpos, Evangelos; Delimpasi, Sossana; Kotsopoulou, Maria; Michalis, Eurydiki; Vadikolia, Chrysanthi; Kyrtsonis, Marie-Christine; Symeonidis, Argiris; Giannakoulas, Nikolaos; Vadikolia, Chrissa; Michael, Michalis; Kalpadakis, Christina; Gougopoulou, Theodora; Prokopiou, Chrystalla; Kaiafa, Georgia; Christoulas, Dimitrios; Gavriatopoulou, Maria; Giannopoulou, Evlampia; Labropoulou, Vasiliki; Verrou, Evgenia; Kastritis, Efstathios; Konstantinidou, Pavlina; Anagnostopoulos, Achilles; Dimopoulos, Meletios A

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

有症状的华氏巨球蛋白血症患者的竞争风险生存分析:疾病无关死亡率和基于利妥昔单抗的一线治疗的影响

Kastritis, Efstathios; Kyrtsonis, Marie-Christine; Morel, Pierre; Gavriatopoulou, Maria; Hatjiharissi, Evdoxia; Symeonidis, Argirios S; Vassou, Amalia; Repousis, Panagiotis; Delimpasi, Sossana; Sioni, Anastasia; Michalis, Evrydiki; Michael, Michail; Vervessou, Elina; Voulgarelis, Michael; Tsatalas, Costantinos; Terpos, Evangelos; Dimopoulos, Meletios A